Indofarma Tbk
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutic… Read more
Indofarma Tbk (INAF) - Total Assets
Latest total assets as of September 2025: Rp581.56 Billion IDR
Based on the latest financial reports, Indofarma Tbk (INAF) holds total assets worth Rp581.56 Billion IDR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Indofarma Tbk - Total Assets Trend (2000–2024)
This chart illustrates how Indofarma Tbk’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Indofarma Tbk - Asset Composition Analysis
Current Asset Composition (December 2024)
Indofarma Tbk's total assets of Rp581.56 Billion consist of 21.7% current assets and 78.3% non-current assets.
| Asset Category | Amount (IDR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp0.00 | 1.6% |
| Accounts Receivable | Rp46.92 Billion | 7.6% |
| Inventory | Rp33.33 Billion | 5.4% |
| Property, Plant & Equipment | Rp383.13 Billion | 62.0% |
| Intangible Assets | Rp2.88 Billion | 0.5% |
| Goodwill | Rp0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Indofarma Tbk's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Indofarma Tbk's current assets represent 21.7% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, down from 9.6% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is property, plant & equipment at 62.0% of total assets.
Indofarma Tbk Competitors by Total Assets
Key competitors of Indofarma Tbk based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Indofarma Tbk - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Indofarma Tbk generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Indofarma Tbk is currently not profitable relative to its asset base.
Indofarma Tbk - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.13 | 0.15 | 1.36 |
| Quick Ratio | 0.10 | 0.07 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rp-1.09 Trillion | Rp -1.21 Trillion | Rp 297.98 Billion |
Indofarma Tbk - Advanced Valuation Insights
This section examines the relationship between Indofarma Tbk's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.53 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -18.6% |
| Total Assets | Rp618.16 Billion |
| Market Capitalization | $4.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Indofarma Tbk's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Indofarma Tbk's assets decreased by 18.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Indofarma Tbk (2000–2024)
The table below shows the annual total assets of Indofarma Tbk from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Rp618.16 Billion | -18.64% |
| 2023-12-31 | Rp759.83 Billion | -50.47% |
| 2022-12-31 | Rp1.53 Trillion | -23.75% |
| 2021-12-31 | Rp2.01 Trillion | +17.42% |
| 2020-12-31 | Rp1.71 Trillion | +23.80% |
| 2019-12-31 | Rp1.38 Trillion | -4.05% |
| 2018-12-31 | Rp1.44 Trillion | -5.72% |
| 2017-12-31 | Rp1.53 Trillion | +10.73% |
| 2016-12-31 | Rp1.38 Trillion | -9.92% |
| 2015-12-31 | Rp1.53 Trillion | +22.86% |
| 2014-12-31 | Rp1.25 Trillion | -3.57% |
| 2013-12-31 | Rp1.29 Trillion | +8.91% |
| 2012-12-31 | Rp1.19 Trillion | +6.61% |
| 2011-12-31 | Rp1.11 Trillion | +51.90% |
| 2010-12-31 | Rp733.96 Billion | +0.81% |
| 2009-12-31 | Rp728.03 Billion | -24.62% |
| 2008-12-31 | Rp965.81 Billion | -4.32% |
| 2007-12-31 | Rp1.01 Trillion | +46.95% |
| 2006-12-31 | Rp686.94 Billion | +32.40% |
| 2005-12-31 | Rp518.82 Billion | -0.97% |
| 2004-12-31 | Rp523.92 Billion | -17.62% |
| 2003-12-31 | Rp635.96 Billion | -21.49% |
| 2002-12-31 | Rp810.03 Billion | -0.20% |
| 2001-12-31 | Rp811.62 Billion | +50.81% |
| 2000-12-31 | Rp538.17 Billion | -- |